Global Companion Animal Drugs Market: By Product Type (Antimicrobials, Ectoparasiticides, Endoparacitides, Endectoparaciticides, Anti-inflammatory Drugs, Anti-Obesity Drugs, Behavioral Products, Biologic Drugs and Others), By Animal Type (Feline, canine, and Equine), By Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals, Veterinary Clinics, and E-Commerce), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

September 2017 | 190 pages | ID: G528944CB14EN
Precision Business Insights (PBI)

Abstracts

Global Companion Animal Drugs Market Report Description:

Companion animal drugs market report gives comprehensive outlook on companion animal drugs market across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on companion animal drugs market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, animal type, route of administration, distribution channel, and geographic regions. This report studies companion animal drugs market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, companion animal drugs market report includes animal demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed companion animal drugs market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the companion animal drugs market report include suppliers, manufacturers, marketers, policy makers, and veterinary healthcare service providers engaged in manufacturing and supply of companion animal drug products.

Global Companion Animal Drugs Market:

Global companion animal drugs market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of 5.6% over 2017-2023. Market for companion animal drugs projected to reach US$ XX Mn by 2023 owing to rising human and companion animals bondage by means of adoption across the globe.

Rising Pet companionship to the human beings expected to drive the companion animal drugs market over the forecast period

Companion animals have been trusted for their companionship to the human throughout the history and keeping the companion animals healthy is a top priority for caregivers everywhere in the world, which is expected to drive the companion animal market over six years forecast period. Moreover, several studies on human and companion animals’ interactions showed that association with companion animals results in positive health benefits. Therefore, it is essential to veterinarians and caregivers to give utmost attention to companion animal health as companion animals are primary source of zoonotic diseases spread to humans and vice versa, this is expected to create significant market demand for companion animal drugs over the forecast period.

Increasing per pet expenditure in recent times expected to drive market revenue growth

Several respondents and pet owners reveled that pet expenditure is increasingly becoming integral part of their monthly expenditure and companion animals are part of several families across the developed and developing economies. Moreover, rising interactions between pets and human beings prompting the care givers and pet owners to adopt better healthcare services to the companion animals this is projected to drive market revenue growth over the forecast period.

North America accounted for larger market revenue share in global companion animal drugs market

U.S. market dominated the companion animal drugs market with largest market share in North America market with moderate growth rate. Europe companion animal drugs market holds significant share in global companion animal drugs market and projected to grow at significant growth over the forecast period.

COMPETITION ASSESSMENT

Key players profiles in the global Companion Animal Drugs market include:

• Bayer AG (Germany)
• Boehringer Ingelheim GmbH (Germany)
• Ceva Santé Animale (France)
• Eli Lilly and Company (U.S)
• Hester biosciences (India)
• Merck & Co., Inc. (U.S)
• Vétoquinol S.A. (France)
• Virbac S.A. (France)
• Zoetis Inc. (U.S)

Players in the companion animal drugs market are launching the products in the market to garner larger market share. For instance, in July 2016, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, received U.S. Food and Drug Administration’s approval for BRAVECTO (fluralaner topical solution) a topical treatment for fleas and ticks for both cats and dogs.

KEY FINDINGS OF THE REPORT:

• Companion animal drugs market expanding at 5.6% CAGR over 2017 to 2023 to reach market value of US$ XX Mn by 2023 owing to increased adoption pet animals and rising zoonotic diseases
• Based on product type paraciticides accounted for larger market revenue share in 2016 and projected gain larger market revenue share over the forecast period
• Veterinary clinics distribution channel is the prime source for companion drugs across the globe and expected to remain attractive over the forecast period
• Players focusing on launching products to retain market position in global companion animal drugs market

KEY FEATURES OF THE REPORT:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Product Type

• Antimicrobials
• Ectoparasiticides
• Endoparacitides
• Endectoparaciticides
• Anti-inflammatory Drugs
• Anti-Obesity Drugs
• Behavioral Products
• Biologic Drugs
• Others

By Animal Type

• Feline
• Canine
• Equine

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

Distribution Channel

• Veterinary Pharmacies
• Veterinary Hospitals
• Veterinary Clinics
• E-Commerce

Geography

• North America
• U.S
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
• Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa

Rest of MEA

Contents

1. RESEARCH METHODOLOGY

1.1. Secondary and Primary research
  1.1.1. Secondary Sources
  1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms

2. SCOPE OF STUDY

2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL COMPANION ANIMAL DRUGS MARKET DYNAMICS

4.1. Drivers
  4.1.1. Economic Drivers
  4.1.2. Demand Side Drivers
  4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis

6. GLOBAL COMPANION ANIMAL DRUGS MARKET ANALYSIS, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Antimicrobials
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Ectoparasiticides
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Endoparacitides
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Endectoparaciticides
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. Anti-Inflammatory Drugs
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.6. Anti-Obesity Drugs
  6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.7. Behavioral Products
  6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.8. Biologic Drugs
  6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.9. Others
  6.9.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL COMPANION ANIMAL DRUGS MARKET ANALYSIS, BY ANIMAL TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Feline
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Canine
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Equine
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. GLOBAL COMPANION ANIMAL DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Oral
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Parenteral
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Topical
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Others
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. GLOBAL COMPANION ANIMAL DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Veterinary Pharmacies
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Veterinary Hospitals
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Veterinary Clinics
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.4. E-Commerce
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10. GLOBAL COMPANION ANIMAL DRUGS MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. North America Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.1.1. Antimicrobials
    10.1.1.2. Ectoparasiticides
    10.1.1.3. Endoparacitides
    10.1.1.4. Endectoparaciticides
    10.1.1.5. Anti-inflammatory Drugs
    10.1.1.6. Anti-Obesity Drugs
    10.1.1.7. Behavioral Products
    10.1.1.8. Biologic Drugs
    10.1.1.9. Others
  10.1.2. Animal Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.2.1. Feline
    10.1.2.2. Canine
    10.1.2.3. Equine
  10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.3.1. Veterinary Pharmacies
    10.1.3.2. Veterinary Hospitals
    10.1.3.3. Veterinary Clinics
    10.1.3.4. E-Commerce
  10.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.4.1. Oral
    10.1.4.2. Parenteral
    10.1.4.3. Topical
    10.1.4.4. Others
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.5.1. U.S
    10.1.5.2. Canada
10.2. Europe Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.2.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.1.1. Drug Therapy
      10.2.1.1.1. Gemcitabine Combination Therapy
      10.2.1.1.2. 5-fluorouracil Combination Therapy
      10.2.1.1.3. Capecitabine Combination Therapy
      10.2.1.1.4. Gemcitabine Alone
    10.2.1.2. Radiation Therapy
      10.2.1.2.1. Brachytherapy
      10.2.1.2.2. External Beam Radiation Product (EBRT)
    10.2.1.3. Surgery
  10.2.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  10.2.3. Intrahepatic Bile Duct Cancer
  10.2.4. Extrahepatic Bile Duct Cancer
    10.2.4.1. Perihilar Bile Duct Cancer
    10.2.4.2. Distal Extrahepatic Bile Duct Cancer
  10.2.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.5.1. Hospitals
    10.2.5.2. Pharmacies
    10.2.5.3. Oncology Centers
    10.2.5.4. Drug Stores
  10.2.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.6.1. Germany
    10.2.6.2. France
    10.2.6.3. U.K
    10.2.6.4. Italy
    10.2.6.5. Spain
    10.2.6.6. Russia
    10.2.6.7. Poland 10.2.6.8. Rest of Europe
10.3. Asia-Pacific Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.3.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.1.1. Drug Therapy
      10.3.1.1.1. Gemcitabine Combination Therapy
      10.3.1.1.2. 5-fluorouracil Combination Therapy
      10.3.1.1.3. Capecitabine Combination Therapy
      10.3.1.1.4. Gemcitabine Alone
    10.3.1.2. Radiation Therapy
      10.3.1.2.1. Brachytherapy
      10.3.1.2.2. External Beam Radiation Product (EBRT)
    10.3.1.3. Surgery
  10.3.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  10.3.3. Intrahepatic Bile Duct Cancer
  10.3.4. Extrahepatic Bile Duct Cancer
    10.3.4.1. Perihilar Bile Duct Cancer
    10.3.4.2. Distal Extrahepatic Bile Duct Cancer
  10.3.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.5.1. Hospitals
    10.3.5.2. Pharmacies
    10.3.5.3. Oncology Centers
    10.3.5.4. Drug Stores
  10.3.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.6.1. Japan
    10.3.6.2. China
    10.3.6.3. India
    10.3.6.4. Australia & New Zealand 10.3.6.5. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
    10.3.6.6. South Korea
10.4. Latin America Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.4.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.1.1. Drug Therapy
      10.4.1.1.1. Gemcitabine Combination Therapy
      10.4.1.1.2. 5-fluorouracil Combination Therapy
      10.4.1.1.3. Capecitabine Combination Therapy
      10.4.1.1.4. Gemcitabine Alone
    10.4.1.2. Radiation Therapy
      10.4.1.2.1. Brachytherapy
      10.4.1.2.2. External Beam Radiation Product (EBRT)
    10.4.1.3. Surgery
  10.4.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  10.4.3. Intrahepatic Bile Duct Cancer
  10.4.4. Extrahepatic Bile Duct Cancer
    10.4.4.1. Perihilar Bile Duct Cancer
    10.4.4.2. Distal Extrahepatic Bile Duct Cancer
  10.4.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.5.1. Hospitals
    10.4.5.2. Pharmacies
    10.4.5.3. Oncology Centers
    10.4.5.4. Drug Stores
  10.4.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.6.1. Brazil
    10.4.6.2. Mexico
    10.4.6.3. Argentina
    10.4.6.4. Venezuela
    10.4.6.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.5.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.1.1. Drug Therapy
      10.5.1.1.1. Gemcitabine Combination Therapy
      10.5.1.1.2. 5-fluorouracil Combination Therapy
      10.5.1.1.3. Capecitabine Combination Therapy
      10.5.1.1.4. Gemcitabine Alone
    10.5.1.2. Radiation Therapy
      10.5.1.2.1. Brachytherapy
      10.5.1.2.2. External Beam Radiation Product (EBRT)
    10.5.1.3. Surgery
  10.5.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  10.5.3. Intrahepatic Bile Duct Cancer
  10.5.4. Extrahepatic Bile Duct Cancer
    10.5.4.1. Perihilar Bile Duct Cancer
    10.5.4.2. Distal Extrahepatic Bile Duct Cancer
  10.5.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.5.1. Hospitals
    10.5.5.2. Pharmacies
    10.5.5.3. Oncology Centers
    10.5.5.4. Drug Stores
  10.5.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.6.1. Gulf Cooperation Council (GCC) Countries
    10.5.6.2. Israel
    10.5.6.3. South Africa
    10.5.6.4. Rest of MEA

11. COMPETITION LANDSCAPE

11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  11.2.1. Bayer AG (Germany)
  11.2.2. Boehringer Ingelheim GmbH (Germany)
  11.2.3. Ceva Santé Animale (France)
  11.2.4. Eli Lilly and Company (U.S)
  11.2.5. Hester biosciences (India)
  11.2.6. Merck & Co., Inc. (U.S)
  11.2.7. Vétoquinol S.A. (France)
  11.2.8. Virbac S.A. (France)
  11.2.9. Zoetis Inc. (U.S)